Next Article in Journal
Testing of the Survivin Suppressant YM155 in a Large Panel of Drug-Resistant Neuroblastoma Cell Lines
Previous Article in Journal
WNK1 Kinase Stimulates Angiogenesis to Promote Tumor Growth and Metastasis
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Cancers
Volume 12
Issue 3
10.3390/cancers12030576
cancers-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

NUDT7 Loss Promotes KrasG12D CRC Development

by
Jinsoo Song
1,2,
Sujeong Park
1,
Jinjoo Oh
1,
Deokha Kim
1,
Ji Hyun Ryu
3,
Won Cheol Park
4,
In-Jeoung Baek
5,
Xi Cheng
6,7,
Xin Lu
6,* and
Eun-Jung Jin
1,2,*
1
Department of Biological Sciences, College of Natural Sciences, Wonkwang University, Iksan, Chunbuk 54538, Korea
2
Integrated Omics Institute, Wonkwang University, Iksan, Chunbuk 54538, Korea
3
Department of Carbon Convergence Engineering, College of Engineering, Wonkwang University, Iksan, Chunbuk 54538, Korea
4
Department of Surgery, Wonkwang University School of Medicine, Iksan, Chunbuk 54538, Korea
5
Asan Institute for Life Sciences, University of Ulsan College of Medicine, Seoul, 05505, Korea
6
Department of Biological Sciences, Boler-Parseghian Center for Rare and Neglected Diseases, Harper Cancer Research Institute, University of Notre Dame, Notre Dame, IN 46556, USA
7
Department of General Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China
*
Authors to whom correspondence should be addressed.
Cancers 2020, 12(3), 576; https://doi.org/10.3390/cancers12030576
Submission received: 29 October 2019 / Revised: 2 January 2020 / Accepted: 27 February 2020 / Published: 2 March 2020
Browse Figures
Versions Notes

Abstract

:
Studies have suggested that dysregulation of peroxisomal lipid metabolism might play an important role in colorectal cancer (CRC) development. Here, we found that KrasG12D-driven CRC tumors demonstrate dysfunctional peroxisomal β-oxidation and identified Nudt7 (peroxisomal coenzyme A diphosphatase NUDT7) as one of responsible peroxisomal genes. In KrasG12D-driven CRC tumors, the expression level of Nudt7 was significantly decreased. Treatment of azoxymethane/dextran sulfate sodium (AOM/DSS) into Nudt7 knockout (Nudt7−/−) mice significantly induced lipid accumulation and the expression levels of CRC-related genes whereas xenografting of Nudt7-overexpressed LS-174T cells into mice significantly reduced lipid accumulation and the expression levels of CRC-related genes. Ingenuity pathway analysis of microarray using the colon of Nudt7−/− and Nudt7+/+ mice treated with AOM/DSS suggested Wnt signaling as one of activated signaling pathways in Nudt7−/− colons. Upregulated levels of β-catenin were observed in the colons of KrasG12D and AOM/DSS-treated Nudt7−/− mice and downstream targets of β-catenin such as Myc, Ccdn1, and Nos2, were also significantly increased in the colon of Nudt7−/− mice. We observed an increased level of palmitic acid in the colon of Nudt7−/− mice and attachment of palmitic acid-conjugated chitosan patch into the colon of mice induced the expression levels of β-catenin and CRC-related genes. Overall, our data reveal a novel role for peroxisomal NUDT7 in KrasG12D-driven CRC development.

1. Introduction

Colorectal cancer (CRC) is one of the most common cancers, with over one million new cases diagnosed worldwide each year. It is the third most common malignancy and the second most common cause of cancer mortality [1]. Tumorigenesis of CRC involves a multi-step process through the accumulations of genetic and epigenetic alterations. High-penetrance mutations of the mismatch repair genes (Mlh1, DNA mismatch repair protein Mlh1; Msh2, DNA mismatch repair protein Msh2; Msh6, DNA mismatch repair protein Msh6; Pms2, mismatch repair endonuclease Pms2; Apc, adenomatous polyposis coli protein; Mutyh, adenine DNA glycosylase; Smad4, SMAD family member 4; Bmpr1A, bone morphogenetic protein receptor type 1A; Stk11/Lkb1, serine-threonine kinase 11; Pten, phosphatase and tensin homolog; Axin2, axis inhibition protein 2; Pole, DNA polymerase epsilon, catalytic subunit; Pold1, DNA polymerase delta 1, catalytic subunit) have been reported as CRC predisposing factors [2]. Exome sequencing of common familial CRC suggested 11 novel candidate CRC susceptibility genes, including Uaca, Sfxn4, Twsg1, Psph, Nudt7, Znf490, Prss37, Ccdc18, Pradc1, Mrpl3, and Akr1c4, with rare truncating variants [3]. Although many molecular events have been identified, new molecules that play a role in this process remain to be discovered, and are crucial for the development of improved therapeutic approaches.
Currently, in CRC, drugs either targeting angiogenesis (bevacizumab, aflibercept, and ramucirumab) or targeting the epidermal growth factor receptor (EGFR; cetuximab and panitumumab) have been developed [4]. Cetuximab and panitumumab are both monoclonal antibodies directed against the extracellular domain of the EGFR and block the downstream RAS (Ras proto-oncogene, GTPase)-RAF (RF proto-oncogene serin/threonine-protein kinase)-MEK (mitogen-activated protein kinase kinase 1)-ERK signaling pathway [5,6]. However, the clinical response of CRC to anti-EGFR Abs is poor for tumors with the Kirsten rat sarcoma viral oncogene homolog (Kras) mutation mostly at codons 12, 13, or 61 [7,8], which are found in 40% of metastatic CRCs. Identifying the molecular pathogenic and regulatory processes of CRC with Kras mutation (Krasmut) will likely provide promising strategies for controlling Krasmut CRC. Thus, a deeper understanding of the molecular and genetic networks that control the initiation and progression of Krasmut CRC is essential.
Lipid metabolism, particularly fatty acid β-oxidation, is an essential process for cancer cell proliferation, differentiation, motility, and growth [9,10]. An appropriate ratio between saturated fatty acids (SFAs) and monounsaturated fatty acids (MUFAs) is required for proper membrane fluidity and cell function, and an increased amount of MUFAs has been observed in several cancers [11,12]. Stearoyl-CoA (Coenzyme A) desaturase-1 (SCD1), the rate-limiting enzyme converting SFAs into MUFAs, has been described to be upregulated in several types of human tumors and is known to be correlated with malignant transformation, proliferation, and survival of cancer cells [13]. Acyl-CoA synthetases (ACSs), the rate-limiting enzyme converting long chain fatty acids (LCFAs) to acyl-CoA, is also related to carcinogenesis [14]. A study demonstrated that the Kras-dependent regulation of lipid metabolism is a critical factor for lung tumorigenesis [15] and fatty acid-induced inflammatory mediators such as prostaglandin E2, leukotriene B4, interleukin 1β, and tumor necrosis factor α, are known to act as stimulatory factors for cancer cell growth and proliferation [16].
In mammalian cells, peroxisome is the main subcellular organelle involved in the β-oxidation pathway, a key pathway for the breakdown of fatty acids [17,18]. In peroxisomes, the first step of fatty acid oxidation is the conversion reaction of fatty acids into acyl-CoA. Peroxisomal β-oxidation mainly concerns very long chain fatty acids (VLCFAs, >C22) and branched fatty acids, as well as some prostaglandins and leukotrienes [19,20,21]. Even though the importance of peroxisome in the regulation of various cellular functions including lipid metabolism has emerged, our knowledge of the function and role of peroxisomes is limited.
In this study, we evaluate the importance of peroxisomal function in KrasG12D CRC and identify peroxisomal coenzyme A diphosphatase NUDT7 (NUDT7) as a potent tumor suppressor to restrict KrasG12D CRC progression.

2. Results

2.1. Peroxisomal Dysfunction Is Responsible for Dysregulation of Lipid Metabolism in KrasG12D CRC

To assess the alteration of lipid metabolism in KrasG12D CRC compared with KrasWT CRC, we analyzed lipid reactive oxygen species (ROS) and lipid accumulation in KrasG12D CRC cells (SNU-407, SNU-C2A, and LS-174T) and KrasWT cells (COLO-320DM, HT29, and Caco2). The number of BODIPY and lipid ROS-positive cells was significantly increased (average of 3.95-fold of KrasWT CRC cells and 3.77-fold of KrasWT CRC cells in BODIPY and lipid ROS-positive cells, respectively) in KrasG12D CRC cells compared with those in KrasWT CRC cells (Figure 1A,B). The expression levels of genes in lipid metabolism such as Abca1, Acsl1, Agpat1, Cd36, Fasn, Ldlr, Pparg, and Scd1, were dramatically increased in KrasG12D CRC cells (Figure 1C). We also observed the upregulation of carnitine palmitoyltransferase-1 (CPT1) (662.85-fold of KrasWT CRC tumor), fatty acid binding protein 4 (FABP4) (7.87-fold of KrasWT CRC tumor), and SCD1 (5.1-fold of KrasWT CRC tumor) in KrasG12D CRC tumors (n = 4) compared with KrasWT CRC tumors (Figure 1D). Gene set enrichment analysis (GSEA) using GSE41258 (186 primary tumors compared with 54 normal colons) and GSE12398 (KrasG12D transfected Colo741 cells compared with KrasWT transfected Colo741 cells), showed decreased expression of peroxisome-related genes in KrasG12D CRC tumors (Figure 1E).
To identify the factor responsible for peroxisomal lipid dysregulation in KrasG12D CRC, we analyzed the expression levels of 94 peroxisomal genes listed in the peroxisome database [22] and performed multiple t-tests. Among the genes tested, the expression level of Crat was significantly increased (p ≤ 0.05), whereas the expression level of Nudt7 was significantly decreased (p ≤ 0.05) in KrasG12D CRC cells (LS174T, SNU-407, and SNU-C2A) compared with KrasWT CRC cells (Caco2, HT29, and COLO-320DM) with different genetic backgrounds [23,24,25] (Figure S1). In human CRC tumors, the expression levels of Nos2, Sod2, Acot2, Xdh, Acot1, Crat, Crot, Phyh, Sod1, and Hao1 were significantly increased (p ≤ 0.05), whereas the expression levels of Nudt7, Acsl5, Abcd3, Acsl3, Far1, Pex12, Rhoc, Acsl4, Ehhadh, Ech1, Dnajc10, Acaa1, Agps, Acsf3, Trim37, Pex6, and Hmgcl were significantly decreased (p ≤ 0.05) in KrasG12D CRC tumors (Figure S1B,C; including functional categories for these genes according to peroxisome database). Comparison of gene profiles showed that Crat was significantly increased whereas Nudt7 was significantly decreased both in KrasG12D CRC cells and KrasG12D CRC patients tumors (Figure S1A,B). The involvement of the carnitine system including Crat is well-known. The carnitine system alters the metabolic plasticity and supplies an energetic and biosynthetic demand of cancer cells [26]. Higher carnitine O-acetyltransferase (CRAT) expression is also known to contribute to maintaining a high metabolic plasticity in cancers and suppressing the carnitine system [27]. However, the function of Nudt7 in cancer has not been well studied. Analysis of GSE8671 (comparison between 32 prospectively collected adenomas and normal mucosa from the same individuals) [28] also showed a significant decrease in Nudt7 in CRC (Figure 2A). We observed a drastic decrease in the level of Nudt7 in KrasG12D CRC compared to KrasWT CRC tumors (Figure 2B).

2.2. Dysregulation of Lipid Metabolism by Nudt7 Suppression Is Involved in Development and Progression of KrasG12D CRC

To identify the functional role of Nudt7 in lipid homeostasis, we analyzed lipid accumulation via modulation of Nudt7. Lipid accumulation and the number of BODIPY-positive cells (average of 0.2-fold with Nudt7 overexpression (Nudt7), 1.8-fold with Nudt7 knockdown (shNudt7) compared to KrasG12D CRC cells), were significantly increased in KrasG12D CRC cell lines, SNU-407, and SNU-C2A, and this increase was dramatically reduced by overexpression of Nudt7 (Figure S2). Knockdown of Nudt7 into KrasWT Caco2 cells significantly increased the accumulation of medium chain fatty acids (MCFAs), LCFAs, and VLCFAs (Figure S3A). The increased expression levels of lipogenic genes such as Acaca, Cd36, Cpt1b, Fasn, Ldlr, Pparg, Scd1, and Vldlr by shNudt7 into KrasG12D cells, SNU-407 and SNU-C2A (Figure S3B) were recovered by Nudt7 restoration. Moreover, increased levels of Abca1, Acsl1, Agpat1, and Scd1 by KrasG12D overexpression (KrasG12D) into KrasWT Caco2 cells (Figure S4A) were recovered by Nudt7 restoration. In a genetically engineered mouse model of inducible CRC, Villin-CreERT2, Apcf/f, Trp53f/f, and tetO-LSL-KrasG12D [29], the expression levels of CPT1, FABP4, and SCD1 (Figure S4B) were significantly upregulated whereas the expression level of Nudt7 was dramatically decreased when KrasG12D was turned on (+DOX; KrasON; 0.51-fold of KrasOFF) (Figure 2C). The subcutaneous mouse model of KrasG12D cells, LS-174T, showed that overexpression of Nudt7 significantly decreased tumor mass (3.36-fold of control (Con))(Figure 3A,B). The number of BODIPY-positive cells (0.61-fold of Con)(Figure 3C), the expression level of lipogenic genes such as Abca1 (0.53-fold of Con), Acsl1 (0.74-fold of Con), Agpat1 (0.77-fold of Con), and Scd1 (0.65-fold of Con)(Figure 3D), and the number of Ki67- (0.27-fold of Con), FASN- (fatty acid synthase; 0.5-fold of Con), ACC- (acetyl-CoA carboxylase α; 0-64 fold of Con), CPT- (0.2-fold of Con), FABP4- (0.2-fold of Con), and SCD1-positive cells (0.5-fold of Con)(Figure 3E) were also significantly decreased in xenograft tumors with Nudt7 overexpression.
To identify the role of Nudt7 in the development of CRC, we induced colonic polyp formation using an azoxymethane/dextran sulfate sodium (AOM/DSS) method using Nudt7 knock-out (KO, Nudt7−/−) mice [30]. AOM/DSS challenge has been shown to induce acute inflammation in the colon with increased immune cell infiltration [31]. Lymphocyte antigen 6 complex locus G6D (LY6G), protein tyrosine phosphatase receptor type C (CD45), and adhesion G protein-coupled receptor E1 (F4/80) are used as inflammatory infiltration marker for colon cancer progression and metastasis marker [27,32,33]. Nudt7−/− mice developed more polyps (Figure 4A) and adenocarcinoma (Figure S5) and showed the dramatically increased Ki67- (expressed in colonic glands and proliferating cells; 1.32 fold of Nudt7−/−_AOM/DSS colon), F4/80- (expressed in immune cells; 2.79 fold of Nudt7−/−_AOM/DSS colon), LY6G- (expressed immune cells; 2.47 fold of Nudt7−/−_AOM/DSS colon), and SCD1- (3.70 fold of Nudt7−/−_AOM/DSS colon) positive cells in colons (Figure 4B,C). The increased levels of peroxisomal coenzyme A diphosphatase 7 (NUDT7) and acyl-CoA oxidase 1 (ACOX1) expressed in the epithelial cells and colonic glands in Nudt7+/+_AOM/DSS colon were significantly decreased in Nudt7−/−_AOM/DSS colon (Figure 4C). The expression level of genes involved in CRC progression [34] and target genes of KrasG12D mutation [35,36] (Figure 4D,E) were also significantly increased in colons of Nudt7−/− mice compared to the those of Nudt7+/+ _AOM/DSS mice.

2.3. Increased Palmitic Acid Level by Nudt7 Suppression Is Responsible for CRC Development through Activation of Wnt/β-Catenin Signaling

Ingenuity pathway analysis (IPA), using microarray data of Nudt7+/+ and Nudt7−/− colons treated with AOM/DSS, suggested the Wnt/β-catenin signaling pathway as one of the upregulated pathways (Figure 5A) in Nudt7−/− colons challenged with AOM/DSS. IPA indicated the increase in the concentration of lipids as an enriched molecular and cellular function in Nudt7−/− colons (Figure 5B). Significantly increased levels of Ctnnb1 (186 tumor vs. 54 normal; 1.55-fold) and decreased levels of Nudt7 (0.93-fold) were also observed in 7 KrasG12D cell lines (CL-40, Colo678, EB, IS1, IS3, LS174T, and TC71 cell line) compared with 12 KrasWT cell lines (Caco2, CL-34, Co115, Colo205, Colo320, HT29, KM12, NCI-H508, RKO, and SW48 cell line) and Bittner colons according to analysis of GSE41258 and Oncomine (Figure 5C). We found that the expression level of β-catenin was significantly increased both in Nudt7−/− mice colons treated with AOM/DSS and the patient colon of KrasG12D tumor (Figure 5D). The expression levels of β-catenin target genes, such as Myc (3.3-fold of Nudt7+/+ mice colon), Ccnd1 (4.8-fold of Nudt7+/+ mice colon), Nos2 (2.2-fold of Nudt7+/+ mice colon), Mmp14 (2.5-fold of Nudt7+/+ mice colon), and Cd44 (5.2-fold of Nudt7+/+ mice colon), were also significantly increased in Nudt7−/− mice colons compared with Nudt7+/+ mice colons (Figure 5E). Restoration of Nudt7 by tail-vein injection into Nudt7−/− mice significantly reduced the development of adenoma observed in Nudt7−/− mice colons (Figure S6) and the number of FABP4-, FASN-, Ki67-, CD45-, and SCD1-positive cells (Figure S6). Analysis of fatty acid composition using clinical adjacent normal (non-tumor) and CRC tissues as well as Caco2 cells transfected with shCon or shNudt7 showed a significant increase in palmitic acid (PA) (Figure 6A and Table S1), suggesting the possible involvement of Nudt7 in the accumulation of PA. To investigate the involvement of PA in the activation of the Wnt/β-catenin signaling pathway induced by Nudt7, KrasWT Caco2 cells were treated with PA. Exposure of PA into KrasWT Caco2 cells significantly increased the transcription level of Ctnnb1 (Figure 6B and Figure S7B), suggesting that increased levels of palmitic acid by Nudt7 deficiency may be involved in the activation of the Wnt/β-catenin signaling pathway.
For further verification of the PA role in CRC development, we produced the chitosan film (Chi) and chitosan/palmitate (Chi/PA) complex (Figure 6C) which was attached in the colon in Nudt7+/+ mice for a week. We observed a significantly increased number of polyps (Figure 6D). We observed the increase in infiltration of inflammatory cells, a key feature of sporadic adenomatous colonic polyps with an increased number of Ki67-, CD45-, β-catenin-, proliferating cell nuclear antigen (PCNA)-, and F4/80-positive cells (Figure 6E) in the Chi/PA-attached Nudt7+/+ colon polyp. The expression level of genes involved in CRC development and progression also increased in Chi/PA-attached Nudt7+/+ colons (Figure 6F).

3. Discussion

Since lipid metabolism is known to be closely involved in various regulatory and developmental signaling pathways through regulation of cell growth and proliferation [37], it is not surprising that lipogenic regulatory pathways are dysregulated in cancer. Among the cellular organelles involved in lipid metabolism, our laboratory [38] previously suggested the importance of peroxisomes and their inter-connection with mitochondria in maintaining lipid homeostasis. Other studies also suggest that peroxisome plays a central role in cellular lipid metabolism, and particularly in fatty acid oxidation, which cannot be replaced by mitochondria [39,40]. β-oxidation of VLCFAs and branched chain fatty acids preferentially occurs in peroxisomes [41] and patients with peroxisomal disorders show increased serum levels of VLCFAs and branched chain fatty acids [42,43]. Here, in CRC patients, we found elevated levels of VLCFAs, suggesting the possible involvement of peroxisomal dysfunction in the pathogenesis of CRC. We observed high levels of peroxisomal lipid ROS and dysregulation of peroxisomal function in KrasG12D CRC cells compared with KrasWT CRC cells, suggesting that revealing and targeting the underlying mechanisms of peroxisomes in KrasG12D CRC could provide a possible strategy to develop effective therapeutic intervention against Kras-dependent malignancies.
To identify the possible responsible genes in dysregulation of lipid homoeostasis in KrasG12D CRC, transcriptomic analysis identified Nudt7, a peroxisomal gene. NUDT7 is known to mediate the cleavage of CoA, CoA ester, oxidized CoA to 3, 5-adenosine diphosphate (ADP) and 4-phosphopantetheine, and regulates CoA and acyl CoA levels in peroxisome [44,45]. Since the important role of CoA homeostasis in tumor growth and malignant progression has been suggested [46], NUDT7 may play an important role in cancer development by altering CoA pools. However, the exact function and role of NUDT7 has not been well studied. Here, we found that downregulation of Nudt7 leads to VLCFA accumulation, and overexpression of Nudt7 inhibits in vitro proliferation and in vivo xenograft tumor growth of KrasG12D CRC cells. AOM/DSS-challenged Nudt7−/− colon exhibited significant increases in the number of CD45-, F4/80-, and LY6G-positive cells suggesting Nudt7 deficiency may be attributed to the induced number of infiltration immune cells in the colon of AOM/DSS-treated mice. Nudt7 is important in the recruitment of neutrophil and monocytes/macrophages to the inflammatory sites following AOM/DSS challenge and may contribute to the induction of inflammatory cytokines, in line with our findings that show that Nudt7 deficiency stimulates inflammatory responses in mice and humans with osteoarthritis [30]. Moreover, Nudt7−/− mice showed a significantly more pronounced increase in the expression levels of genes involved in the development of CRC, suggesting NUDT7 as a novel potent tumor suppressor for CRC.
Aberrant Wnt signaling is associated with many types of cancers [47,48] suggesting Wnt signaling is an attractive and effective target for therapeutic strategy. Activation of Wnt signaling is frequently observed in human CRC patients [49,50]. Activation of Wnt signaling acts as a key oncogenic driver [32], which is crucial for stem cell maintenance in CRC [51]. The Adenomatous polyposis coli (Apc) tumor suppressor gene interacts with β-catenin [52] and loss of function of Apc results in overactive T-cell factor (TCF) 4/β-catenin signaling [53]. Other studies reported the crosstalk between Wnt/β-catenin and Ras-Erk pathways in the colorectal tumorigenesis [54,55]. Wnt signaling is involved in the stability of Ras through regulation of glycogen synthase kinas 3β-mediated Ras phosphorylation [56]. In hepatocellular carcinoma, Wnt signaling modulates lipid homeostasis in a Ras-dependent manner [57]. In this study, we found that Ras activity modulates the expression level of NUDT7 in an opposite manner, and decreased levels of NUDT7 deregulate lipid homeostasis by the upregulation of Wnt signaling.
Fatty acids can influence cell and tissue metabolism and function through the modulation of immunity, inflammation, and cell signaling [34,35]. Fatty acids are associated with disease risk and contribute to the development of pathological conditions [58,59]. The important role of eicosanoids generated from cyclooxygenase and the lipoxygenase metabolism of arachidonic acid, an n-6 polyunsaturated fatty acid (PUFA), has been suggested in the development of CRC [60]. Here, we found that suppression of Nudt7 induced the accumulation of palmitic acid and this accumulated palmitic acid acted as a driver of Wnt signaling. In several cancers including melanoma, breast cancer, and prostate cancer, cancer cells can uptake, incorporate, and use the exogenous palmitic acid to fuel their pathogenicity [61]. Palmitic acid triggers a non-canonical autophagic response in human cancer cells [62,63]. Palmitic acid increases CRC growth via the modulation of β-adrenergic receptor expression [64] or by modulation of Wnt signaling [65]. Several studies proposed the connection of palmitic acid to cancer promotion/suppression via Wnt/β-catenin signaling [66]. However, the responsible regulatory factor induced by palmitic acid has not been well studied. As a possible regulatory factor, we found that palmitic acid altered the expression level of microRNA (miR)-32-5p and increased the level of miR-32-5p, stimulating Wnt/β-catenin signaling (Figure S7). Introduction of PA into KrasWT Caco2 cells increased the expression level of miR-32-5p known as onco-miRs (Figure S7A) and introduction of miR-32-5p increased expression level of β-catenin (Figure S7B). Furthermore, we observed an increased level of miR-32-5p in CRC patient tumors and Nudt7−/− mice colons (Figure S7C). Several reports [67,68,69] suggested that PA is involved in tumorigenesis by modulating the level of miRs. PA increases the invasiveness of pancreatic cancer cells by decreasing the level of miR-29c [70]. However, the exact function and mechanism of miR-32-5p in CRC induced by suppression of Nudt7 is currently under study in our laboratory.
In summary, our data indicate that suppression of Nudt7 may be responsible for tumorigenic activity of KrasG12D CRC through upregulation of Wnt/β-catenin signaling and accumulation of palmitic acid. Restoration of Nudt7 expression may be developed as a therapeutic strategy to treat patients with CRC, especially cases with KrasG12D mutation.

4. Materials and Methods

4.1. Clinical Samples

Tumor specimens were collected from colorectal cancer patients who underwent resection of colorectal tumors at Wonkwang University Hospital (Iksan, Korea). Sample collection was approved by the Human Subjects Committee of Wonkwang University (Chunbuk, Korea, #WKUH 201401-BR-003).

4.2. Ethics Approval

All the animal experiments were conducted according to the protocol approved by the Animal Care and Use Committee of Wonkwang University (#WKU-18-22). Human colon tissue collection was approved by the Human Subjects Committee of Wonkwang University Hospital and studies were performed in compliance with the institutional guidelines (#WKUH 201401-BR-003). Written informed consent was obtained from all adult patients or at least one guardian of each patient prior to the start of the experiment.

4.3. Animals

The AOM/DSS mouse model [71] was used to examine the mechanisms of human colorectal carcinogenesis. Eight-week-old C57BL/6 wild mice and Nudt7−/− mice [30] were injected intraperitoneally with azoxymethane (AOM; 12.5 mg/kg, Sigma-Aldrich, Louis, MO, USA). We used three cycles of feeding mice with 2% dextran sulfate sodium (DSS) in the drinking water for 5 days, which was replaced on day 6 with autoclaved drinking water without DSS for 5 days. After 30 days, mice were sacrificed, and colon tissues were collected. Nudt7 were cloned into pLenti-CMV-RFP-puro (Abm, Richmond, BC, Canada) lentiviral vector and introduced into the mice by tail-vein injection of Nudt7. Tissue sections (formalin-fixed, paraffin-embedded) of mouse strain Villin-CreERT2; Apcf/f; Trp53f/f; tetO-LSL-KrasG12D were generous gifts from Drs. DePinho and Boutin [29].

4.4. Mouse Xenograft Model

Cancer cells (5 × 105 cells/100 μL/site) were suspended in Matrigel Matrix (Corning, Corning, NY, USA), then subcutaneously injected into the flank of 6-week-old male nude mice (BALB/c-nude). Injected tumor size was measured every day with calipers. Four weeks after injection, tumors were excised from euthanized mice and the tumor mass and weight were measured.

4.5. Cell Culture

Six human colon cancer cell lines with documented Kras G12D mutations (KrasG12D), LS-174T, SNU-407, and SNU-C2A, and three Kras wild-type (KrasWT) colon cancer cells, Caco2, COLO-320DM, and HT29, were purchased from American Type Culture Collection (ATCC, Manassas, VA. USA) or Korea Cell Line Bank (KCLB, Seoul, Korea). Enriched cells were then cultured at sub-clonal density (1–10 cells/cm2) with complete growth medium of each cell line at 37 °C and 5% CO2 atmosphere. Caco2 was cultured in MEM medium (Gibco-Invitrogen, Waltham, MA, USA) supplemented with 20% FBS (Gibco-Invitrogen) at 37 °C and 5% CO2; LS-174T, SNU-407, SNU-C2A, HT-29, and COLO-320DM were cultured in RPMI 1640 medium (Gibco-Invitrogen) with 10% FBS. For the palmitate treatments, cells were treated with 50 μM conjugated palmitate (Sigma-Aldrich) with 10% (w/v) fatty acid free BSA (Sigma-Aldrich) in the DMEM medium. Cell lines used in silico analysis, in vitro, and in vivo experiments, as listed in Table S2.

4.6. Plasmids and Lentiviral Packaging

Nudt7 expression vector was generated by cloning a Nudt7 coding sequence (CDS) in the pLenti-CMV-RFP-puro (Abm) lentiviral vector. Nudt7-specific shRNA was cloned in the pLKO.1-TRC cloning vector (Addgene, Watertown, MA, USA). Empty vector was used as a control. Lentivirus was packaged in HEK293T cells using a Lentifectin (Abm) and concentrated using Lenti-X Concentrator (Clonetech, Mountain View, CA, USA).

4.7. Real-Time PCR

The real-time PCR was performed with RealMIX SYBR Kit, Hi-Rox (Geneer, Daejeon, Korea) in a Step One Plus Real-Time PCR System (Applied Biosystems, Beverly, MA, USA). The reaction mixtures were incubated at 95 °C for 10 min followed by 40 cycles at 95 °C for 10 s, 57 °C for 10 s, and 72 °C for 15 s. 18S ribosomal RNA (Rn18s) or actin beta (Actb) was used as the housekeeping gene. The primer sequence used in this study is listed in Table S3. The fold change in the target genes was calculated based on 2ΔΔCt method [72].

4.8. Quantification of miRNA

For miRNA quantification analysis, the cDNA samples were synthesized using a Mir-X miRNA First Strand Synthesis Kit (Clonetech). Quantitative RT-PCR was performed using Mir-X qRT-PCR SYBR Kit (Clontech) and miR-32-5p-specific forward primer (Genolution) in a Step One Plus Real-Time PCR System. Quantitative RT-PCR conditions were used per the manufacturer’s protocols. The expression of miR-32-5p was normalized with U6 small nuclear RNA (endogenous control; Qiagen, Redwood, CA, USA).

4.9. Peroxisomal Gene Profiling

RNA isolated using RNAiso (TaKaRa, Shiga, Japan) was reverse-transcribed using the AccuRT Genomic DNA Removal Kit (Abm) and oligo dT primers according to the manufacturer’s protocol. The relative abundance of each gene was determined using RT-PCR with specific primers for 94 peroxisomal genes. Actb and Rn18s were used as the endogenous control genes. Gene expression data were analyzed and visualized using PermutMatrix software (version# 1.9.3). The primer sequence used in this study is listed in Table S3.

4.10. Microarray Using RNA Isolated from Paraffin Section

Total RNA was extracted using a RecoverAllTotal Nucleic Acid Isolation kit (ThermoFisher Scientific, Waltham, MA, USA) from FFPE (formalin-fixed paraffin-embedded) CRC samples of Nudt7+/+ and Nudt7−/− mice treated with AOM/DSS. mRNA expression analysis was performed with the Affymetrix GeneChip Whole Transcript PLUS reagent method. cDNA was synthesized using a GeneChip Whole Transcript Amplification Kit. Fragmented sense cDNA was biotin-labeled with TdT (terminal deoxynucleotidyl transferase) using the GeneChip WT Terminal Labeling Kit, and hybridized to the Affymetrix GeneChip Mouse 2.0 ST Array for 16 h at 45 °C. The hybridized array was washed and stained on a GeneChip Fluidics Station 450 and scanned on a GCS3000 Scanner (Affymetrix, Waltham, MA, USA). Signal values were computed using the Affymetrix GeneChip Command Console software.

4.11. Lipid Accumulation and ROS Staining

To measure lipid accumulation, cells were fixed with 4% paraformaldehyde for 10 min. After washing ice-cold 1× PBS, cells were stained with BODIPY or HCS LipidTOX Deep Red neutral lipid stain (ThermoFisher Scientific) for 10 min at room temperature. After PBS washing, cells were stained with DAPI (4’,6-diamidino-2-phenylindole) that was diluted in PBS. Stained cells were visualized and captured with the EVOS FL Auto Cell Imaging System (ThermoFisher Scientific).

4.12. Immunohistochemistry

Colon tissues were fixed in 10% neutral buffered formalin and paraffin-embedded after the dehydrate process. Paraffin-embedded tissue blocks were sliced into 5 μm sections for hematoxylin and eosin (H&E) staining and immunohistochemistry. The sections were deparaffinized, rehydrated, and antigen retrieval was performed using a pressure cooker with 0.01 M citrate buffer at pH 6.0. Intrinsic peroxidase activity was blocked using 1% hydrogen peroxide, and 10% normal goat serum (NGS; Vector Laboratories, Burlingame, CA, USA) was used for 1 h to block. The slides were then incubated overnight at 4 °C. The following antibodies were used for immunohistochemistry overnight at 4 °C (1:200 dilution): ACC (acetyl-CoA carboxylase, Abcam, Cambridge, MA, USA), ACOX1 (acyl-CoA oxidase 1, Abcam), β-catenin (BD Biosciences, San Jose, CA, USA), Ki67 (proliferation marker protein ki-67, Abcam), CD45 (leukocyte common antigen, Abcam), CK19 (cytokeratin 19, epithelial marker, Abcam), CPT1 (carnitine palmitoyltransferase 1, Abcam), FABP4 (fatty acid binding protein, Abcam), FASN (fatty acid synthetase, Abcam), F4/80 (staining for macrophage, ThermoFisher Scientific), LY6G (lymphocyte antigen 6 complex locus G6D, staining for monocytes, granulocytes and neutrophils, ThermoFisher Scientific), PCNA (proliferating cell nuclear antigen, Abcam), and SCD1 (stearoyl-CoA desaturase, Abcam). For mouse NUDT7 immunohistological detection, NUDT7 C-terminal specific peptide (6–20 amino acids, GLPEPVRNNLIDDAK-C) was synthesized by Ab frontier (Seoul, Korea). After incubation with the horseradish peroxidase (HRP)-conjugated secondary antibody (Rabbit or mouse IgG-heavy and light chain antibody, 1:500 dilutions; Bethyl Laboratories, Montgomery, TX, USA) for 1 h at room temperature, antigen signals were detected using the ImmPACT® DAB Peroxidase (HRP) Substrate Kit (Vector Laboratories). All sections were counterstained with hematoxylin. Stained cells were visualized and captured with the Leica Imaging System (Wetzlar, Germany). Positive staining integrity was measured using IHC Profiler of Image J software (version 1.52a, NIH, Bethesda, MD, USA) [73,74].

4.13. Western Blot Analysis

Nuclear and cytoplasmic proteins were prepared using Nuclear/Cytosol Fractionation Kit (BioVision, Milpitas, CA, USA) and concentration was measured using the Pierce BCA Protein Assay Kit (Pierce, Waltham, MA, USA). We electrophoresed 40 μg protein on SDS-PAGE gel and transferred to a nitrocellulose membrane (GE Healthcare Life Sciences, Pittsburgh, PA, USA). Membranes were blocked with 5% skim milk in TBS-0.1% Tween 20 (TBS-T) overnight at 4 °C and immunoblotted with the following antibodies (1:1000 dilution): β-catenin (Abcam), GAPDH (Bioworld Technology, Bloomington, MN, USA), and Histone-H3 (Cell Signaling Technology, Danvers, MA, USA) for 1 h at room temperature. Then, membranes were incubated with the HRP-conjugated secondary antibody (1:2500 dilution) (α-Mouse, Enzo Lifesciences, Farmingdale, NY, USA; α-Rabbit, Enzo Lifesciences, Farmingdale, NY, USA) and the immunoreactive proteins were visualized with SuperSignal West Pico PLUS Chemiluminescent Substrate (ThermoFisher Scientific).

4.14. Preparation of Chitosan Films

Chitosan films were prepared using a solution casting method. Briefly, chitosan (100 mg) was hydrated in 5 mL of 5 N HCl solution, and 45 mL of distilled and deionized water (DDW) were added to the chitosan solution. After its complete dissolution, the chitosan was purified by dialysis (MWCO = 12–14 kDa, Spectra Por, Spectrum Chemical Mfg. Gardena, CA, USA) against DDW for 2 days. The purified chitosan solution was poured onto the Petri dishes (diameter: 35 mm, thickness: 10 mm) for solution casting. The chitosan films were fully dried at 40 °C for one day and maintained in a moisture-free desiccator until use. When we performed the experiments, the chitosan films were treated with sodium hydroxide (NaOH) for 10 min and then were washed with 10 mM PBS solutions several times.

4.15. Preparation of Chitosan/Palmitic Acid Composite Films (Chi/PA films)

To fabricate the Chi/PA films, the chitosan films were firstly prepared as described above. The mixture solutions of chitosan in water and palmitic acid in ethanol were poured onto the chitosan films. The solutions on the chitosan films were dried at 40 °C for one day and were maintained in a moisture-free desiccator until use. When Chi/PA films were treated with NaOH, the rigid structures of films were destroyed and instantaneously transitioned into a hydrogel-like state.

4.16. Gas Chromatograph/Mass spectrometry (GC/MS) Spectrometry

Total lipids were extracted using a chloroform/methanol (2:1 v/v) mixture. The extracted lipids were separated on a Sep-Pak Silica Cartilage column (Waters, Milford, MA, USA) and were transmethylated with 0.5 M CH3ONa in methanol by heating in a sealed tube at 70 °C for 1 h under nitrogen. The fatty acid methyl esters were extracted with hexane. Subsequent GC/MS analysis was performed according to the standard protocol [75].

4.17. Statistical Analysis

Statistical comparisons were performed on GraphPad Prism software (Version 6.0, San Diego, CA, USA) using unpaired t-test, two-way ANOVA, and multiple t-test for multiple variable experiments.

5. Conclusions

Our data indicate that suppression of Nudt7 may be responsible for tumorigenic activity of KrasG12D CRC through upregulation of Wnt/β-catenin signaling and accumulation of palmitic acid. Restoration of Nudt7 expression could be developed as a therapeutic strategy to treat patients with CRC, especially the cases with KrasG12D mutation.

Supplementary Materials

The following are available online at https://www.mdpi.com/2072-6694/12/3/576/s1, Figure S1: Decreased level of Nudt7 expression in KrasG12D tumor, Figure S2: Nudt7 is involved in lipid homeostasis, Figure S3: Dysregulation of lipid homeostasis is induced by Nudt7 deficiency, Figure S4: Dysregulation of lipid metabolism in KrasG12D CRC, Figure S5: Development of adenocarcinoma in Nudt7−/−_AOM/DSS colon, Figure S6: Restoration of Nudt7 into Nudt7−/− mice reduces the expression levels of lipid metabolic and proliferation factors, Figure S7: Palmitic acid induced expression level of miR-32-5p and an increased level of miR-32-5p activates Wnt/β-catenin signaling, Table S1: Lipidomics analysis of CRC using gas chromatography/mass spectrometry (GC/MS), Table S2: List of cell lines used in this study, Table S3: List of real-time PCR primer used in this study.

Author Contributions

Conceptualization, E.-J.J.; data curation, J.S., S.P., J.O., and D.K.; formal analysis: J.S., funding acquisition, J.S. and E.-J.J.; investigation, J.S., X.C., and I.-J.B.; resources, W.C.P., I.-J.B., and J.H.R.; writing—original draft, E.-J.J. and X.L. All authors have read and agreed to the published version of the manuscript.

Funding

This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIP) (2019R1A2C2002157 and 2019R1I1A1A01041827). The authors gratefully thank Peter Kim at the University of Toronto for valuable discussions.

Conflicts of Interest

The authors declare no potential conflicts of interest.

Abbreviations

ABCA1ATP binding cassette subfamily A member 1ACCAcetyl-CoA carboxylase α
ACSL1Acyl-CoA synthetase long chain fatty acid member 1AGPAT1-acyl-glycerol-3-phosphate acyltransferase
AOMAzoxymethaneCD36Fatty acid translocase
CD45Protein tyrosine phosphatase receptor type CCPT1Carnitine palmitoyltransferase
CRCColorectal cancerCK19Cytokeratin 19
DSSDextran sulfateF4/80Adhesion G protein-coupled receptor E1
FABP4Fatty acid binding protein 4FASNFatty acid synthase
Ki67Proliferation marker protein ki-67KRASKirsten rat sarcoma viral oncogene homolog
LCFALong chain fatty acidLDLRLow density lipoprotein receptor
LY6GLymphocyte antigen 6 complex locus G6DMUFAMono-unsaturated fatty acid
NUDT7Peroxisomal coenzyme A diphosphatase NUDT7PPARGPeroxisome proliferator activated receptor gamma
SCD1Stearoyl-CoA desaturase-1SFASaturated fatty acid
VLCFAVery long chain fatty acidVLDLRVery low density lipoprotein receptor

References

  1. Bhandari, A.; Woodhouse, M.; Gupta, S. Colorectal cancer is a leading cause of cancer incidence and mortality among adults younger than 50 years in the USA: A SEER-based analysis with comparison to other young-onset cancers. J. Investig. Med. 2017, 65, 311–315. [Google Scholar] [CrossRef] [Green Version]
  2. Esteban-Jurado, C.; Garre, P.; Vila, M.; Lozano, J.J.; Pristoupilova, A.; Beltran, S.; Abuli, A.; Munoz, J.; Balaguer, F.; Ocana, T.; et al. New genes emerging for colorectal cancer predisposition. World J. Gastroenterol. 2014, 20, 1961–1971. [Google Scholar] [CrossRef] [PubMed]
  3. Gylfe, A.E.; Katainen, R.; Kondelin, J.; Tanskanen, T.; Cajuso, T.; Hanninen, U.; Taipale, J.; Taipale, M.; Renkonen-Sinisalo, L.; Jarvinen, H.; et al. Eleven candidate susceptibility genes for common familial colorectal cancer. PLoS Genet 2013, 9, e1003876. [Google Scholar] [CrossRef] [PubMed]
  4. Martinelli, E.; De Palma, R.; Orditura, M.; De Vita, F.; Ciardiello, F. Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy. Clin. Exp. Immunol. 2009, 158, 1–9. [Google Scholar] [CrossRef] [PubMed]
  5. Van Cutsem, E.; Kohne, C.H.; Hitre, E.; Zaluski, J.; Chang Chien, C.R.; Makhson, A.; D’Haens, G.; Pinter, T.; Lim, R.; Bodoky, G.; et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N. Engl. J. Med. 2009, 360, 1408–1417. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  6. Peeters, M.; Price, T.J.; Cervantes, A.; Sobrero, A.F.; Ducreux, M.; Hotko, Y.; Andre, T.; Chan, E.; Lordick, F.; Punt, C.J.; et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J. Clin. Oncol. 2010, 28, 4706–4713. [Google Scholar] [CrossRef] [PubMed]
  7. Poehlmann, A.; Kuester, D.; Meyer, F.; Lippert, H.; Roessner, A.; Schneider-Stock, R. K-ras mutation detection in colorectal cancer using the Pyrosequencing technique. Pathol. Res. Pract. 2007, 203, 489–497. [Google Scholar] [CrossRef]
  8. Raponi, M.; Winkler, H.; Dracopoli, N.C. KRAS mutations predict response to EGFR inhibitors. Curr. Opin. Pharmacol. 2008, 8, 413–418. [Google Scholar] [CrossRef]
  9. van de Wetering, M.; Sancho, E.; Verweij, C.; de Lau, W.; Oving, I.; Hurlstone, A.; van der Horn, K.; Batlle, E.; Coudreuse, D.; Haramis, A.P.; et al. The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell 2002, 111, 241–250. [Google Scholar] [CrossRef] [Green Version]
  10. Li, Z.; Kang, Y. Lipid Metabolism Fuels Cancer’s Spread. Cell Metab. 2017, 25, 228–230. [Google Scholar] [CrossRef] [Green Version]
  11. Maulucci, G.; Cohen, O.; Daniel, B.; Sansone, A.; Petropoulou, P.I.; Filou, S.; Spyridonidis, A.; Pani, G.; De Spirito, M.; Chatgilialoglu, C.; et al. Fatty acid-related modulations of membrane fluidity in cells: detection and implications. Free Radic. Res. 2016, 50, S40–S50. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  12. Ibarguren, M.; Lopez, D.J.; Escriba, P.V. The effect of natural and synthetic fatty acids on membrane structure, microdomain organization, cellular functions and human health. Biochim. Biophys. Acta 2014, 1838, 1518–1528. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  13. Igal, R.A. Stearoyl-CoA desaturase-1: A novel key player in the mechanisms of cell proliferation, programmed cell death and transformation to cancer. Carcinogenesis 2010, 31, 1509–1515. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  14. Currie, E.; Schulze, A.; Zechner, R.; Walther, T.C.; Farese, R.V., Jr. Cellular fatty acid metabolism and cancer. Cell Metab. 2013, 18, 153–161. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  15. Padanad, M.S.; Konstantinidou, G.; Venkateswaran, N.; Melegari, M.; Rindhe, S.; Mitsche, M.; Yang, C.; Batten, K.; Huffman, K.E.; Liu, J.; et al. Fatty Acid Oxidation Mediated by Acyl-CoA Synthetase Long Chain 3 Is Required for Mutant KRAS Lung Tumorigenesis. Cell Rep. 2016, 16, 1614–1628. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  16. Yu, R.Z.; Lemonidis, K.M.; Graham, M.J.; Matson, J.E.; Crooke, R.M.; Tribble, D.L.; Wedel, M.K.; Levin, A.A.; Geary, R.S. Cross-species comparison of in vivo PK/PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein B-100. Biochem. Pharmacol. 2009, 77, 910–919. [Google Scholar] [CrossRef]
  17. Poirier, Y.; Antonenkov, V.D.; Glumoff, T.; Hiltunen, J.K. Peroxisomal beta-oxidation--a metabolic pathway with multiple functions. Biochim. Biophys. Acta 2006, 1763, 1413–1426. [Google Scholar] [CrossRef] [Green Version]
  18. Reddy, J.K.; Hashimoto, T. Peroxisomal beta-oxidation and peroxisome proliferator-activated receptor alpha: an adaptive metabolic system. Annu. Rev. Nutr. 2001, 21, 193–230. [Google Scholar] [CrossRef]
  19. Stephen, R.L.; Gustafsson, M.C.; Jarvis, M.; Tatoud, R.; Marshall, B.R.; Knight, D.; Ehrenborg, E.; Harris, A.L.; Wolf, C.R.; Palmer, C.N. Activation of peroxisome proliferator-activated receptor delta stimulates the proliferation of human breast and prostate cancer cell lines. Cancer Res. 2004, 64, 3162–3170. [Google Scholar] [CrossRef] [Green Version]
  20. Gou, Q.; Gong, X.; Jin, J.; Shi, J.; Hou, Y. Peroxisome proliferator-activated receptors (PPARs) are potential drug targets for cancer therapy. Oncotarget 2017, 8, 60704–60709. [Google Scholar] [CrossRef] [Green Version]
  21. Youssef, J.; Badr, M. Peroxisome proliferator-activated receptors and cancer: challenges and opportunities. Br. J. Pharmacol. 2011, 164, 68–82. [Google Scholar] [CrossRef] [PubMed]
  22. Schluter, A.; Fourcade, S.; Domenech-Estevez, E.; Gabaldon, T.; Huerta-Cepas, J.; Berthommier, G.; Ripp, R.; Wanders, R.J.; Poch, O.; Pujol, A. PeroxisomeDB: A database for the peroxisomal proteome, functional genomics and disease. Nucleic Acids Res. 2007, 35, D815–822. [Google Scholar] [CrossRef] [PubMed]
  23. Oh, J.H.; Ku, J.L.; Yoon, K.A.; Kwon, H.J.; Kim, W.H.; Park, H.S.; Yeo, K.S.; Song, S.Y.; Chung, J.K.; Park, J.G. Establishment and characterization of 12 human colorectal-carcinoma cell lines. Int. J. Cancer 1999, 81, 902–910. [Google Scholar] [CrossRef]
  24. Ahmed, D.; Eide, P.W.; Eilertsen, I.A.; Danielsen, S.A.; Eknaes, M.; Hektoen, M.; Lind, G.E.; Lothe, R.A. Epigenetic and genetic features of 24 colon cancer cell lines. Oncogenesis 2013, 2, e71. [Google Scholar] [CrossRef]
  25. Medico, E.; Russo, M.; Picco, G.; Cancelliere, C.; Valtorta, E.; Corti, G.; Buscarino, M.; Isella, C.; Lamba, S.; Martinoglio, B.; et al. The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets. Nat. Commun. 2015, 6, 7002. [Google Scholar] [CrossRef]
  26. Melone, M.A.B.; Valentino, A.; Margarucci, S.; Galderisi, U.; Giordano, A.; Peluso, G. The carnitine system and cancer metabolic plasticity. Cell Death Dis 2018, 9, 228. [Google Scholar] [CrossRef] [Green Version]
  27. Valentino, A.; Calarco, A.; Di Salle, A.; Finicelli, M.; Crispi, S.; Calogero, R.A.; Riccardo, F.; Sciarra, A.; Gentilucci, A.; Galderisi, U.; et al. Deregulation of MicroRNAs mediated control of carnitine cycle in prostate cancer: Molecular basis and pathophysiological consequences. Oncogene 2017, 36, 6030–6040. [Google Scholar] [CrossRef]
  28. Sabates-Bellver, J.; Van der Flier, L.G.; de Palo, M.; Cattaneo, E.; Maake, C.; Rehrauer, H.; Laczko, E.; Kurowski, M.A.; Bujnicki, J.M.; Menigatti, M.; et al. Transcriptome profile of human colorectal adenomas. Mol. Cancer Res. 2007, 5, 1263–1275. [Google Scholar] [CrossRef] [Green Version]
  29. Boutin, A.T.; Liao, W.T.; Wang, M.; Hwang, S.S.; Karpinets, T.V.; Cheung, H.; Chu, G.C.; Jiang, S.; Hu, J.; Chang, K.; et al. Oncogenic Kras drives invasion and maintains metastases in colorectal cancer. Genes Dev. 2017, 31, 370–382. [Google Scholar] [CrossRef] [Green Version]
  30. Song, J.; Baek, I.J.; Chun, C.H.; Jin, E.J. Dysregulation of the NUDT7-PGAM1 axis is responsible for chondrocyte death during osteoarthritis pathogenesis. Nat. Commun. 2018, 9, 3427. [Google Scholar] [CrossRef]
  31. Kitajima, S.; Takuma, S.; Morimoto, M. Changes in colonic mucosal permeability in mouse colitis induced with dextran sulfate sodium. Exp. Anim. 1999, 48, 137–143. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  32. Georgoudaki, A.M.; Prokopec, K.E.; Boura, V.F.; Hellqvist, E.; Sohn, S.; Ostling, J.; Dahan, R.; Harris, R.A.; Rantalainen, M.; Klevebring, D.; et al. Reprogramming Tumor-Associated Macrophages by Antibody Targeting Inhibits Cancer Progression and Metastasis. Cell Rep. 2016, 15, 2000–2011. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  33. Ishigamori, R.; Komiya, M.; Takasu, S.; Mutoh, M.; Imai, T.; Takahashi, M. Osteopontin Deficiency Suppresses Intestinal Tumor Development in Apc-Deficient Min Mice. Int. J. Mol. Sci. 2017, 18, 1058. [Google Scholar] [CrossRef] [PubMed]
  34. Ducheix, S.; Peres, C.; Hardfeldt, J.; Frau, C.; Mocciaro, G.; Piccinin, E.; Lobaccaro, J.M.; De Santis, S.; Chieppa, M.; Bertrand-Michel, J.; et al. Deletion of Stearoyl-CoA Desaturase-1 From the Intestinal Epithelium Promotes Inflammation and Tumorigenesis, Reversed by Dietary Oleate. Gastroenterology 2018, 155, 1524–1538. [Google Scholar] [CrossRef]
  35. Kawaguchi, Y.; Hinoi, T.; Saito, Y.; Adachi, T.; Miguchi, M.; Niitsu, H.; Sasada, T.; Shimomura, M.; Egi, H.; Oka, S.; et al. Mouse model of proximal colon-specific tumorigenesis driven by microsatellite instability-induced Cre-mediated inactivation of Apc and activation of Kras. J. Gastroenterol. 2016, 51, 447–457. [Google Scholar] [CrossRef]
  36. Gouw, A.M.; Eberlin, L.S.; Margulis, K.; Sullivan, D.K.; Toal, G.G.; Tong, L.; Zare, R.N.; Felsher, D.W. Oncogene KRAS activates fatty acid synthase, resulting in specific ERK and lipid signatures associated with lung adenocarcinoma. Proc. Natl. Acad. Sci. USA 2017, 114, 4300–4305. [Google Scholar] [CrossRef] [Green Version]
  37. Barrera, G.; Pizzimenti, S.; Dianzani, M.U. Lipid peroxidation: control of cell proliferation, cell differentiation and cell death. Mol. Aspects. Med. 2008, 29, 1–8. [Google Scholar] [CrossRef]
  38. Kim, D.; Song, J.; Kang, Y.; Park, S.; Kim, Y.I.; Kwak, S.; Lim, D.; Park, R.; Chun, C.H.; Choe, S.K.; et al. Fis1 depletion in osteoarthritis impairs chondrocyte survival and peroxisomal and lysosomal function. J. Mol. Med. (Berl) 2016, 94, 1373–1384. [Google Scholar] [CrossRef]
  39. Kohlwein, S.D.; Veenhuis, M.; van der Klei, I.J. Lipid droplets and peroxisomes: key players in cellular lipid homeostasis or a matter of fat--store ’em up or burn ’em down. Genetics 2013, 193, 1–50. [Google Scholar] [CrossRef] [Green Version]
  40. Lodhi, I.J.; Semenkovich, C.F. Peroxisomes: a nexus for lipid metabolism and cellular signaling. Cell Metab. 2014, 19, 380–392. [Google Scholar] [CrossRef] [Green Version]
  41. Wanders, R.J.; Jansen, G.A.; Lloyd, M.D. Phytanic acid alpha-oxidation, new insights into an old problem: a review. Biochim. Biophys. Acta 2003, 1631, 119–135. [Google Scholar] [CrossRef]
  42. Verhoeven, N.M.; Wanders, R.J.; Schor, D.S.; Jansen, G.A.; Jakobs, C. Phytanic acid alpha-oxidation: decarboxylation of 2-hydroxyphytanoyl-CoA to pristanic acid in human liver. J. Lipid. Res. 1997, 38, 2062–2070. [Google Scholar] [PubMed]
  43. Wierzbicki, A.S.; Lloyd, M.D.; Schofield, C.J.; Feher, M.D.; Gibberd, F.B. Refsum’s disease: a peroxisomal disorder affecting phytanic acid alpha-oxidation. J. Neurochem. 2002, 80, 727–735. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  44. Bessman, M.J.; Frick, D.N.; O’Handley, S.F. The MutT proteins or "Nudix" hydrolases, a family of versatile, widely distributed, "housecleaning" enzymes. J. Biol. Chem. 1996, 271, 25059–25062. [Google Scholar] [CrossRef] [Green Version]
  45. Dunn, C.A.; O’Handley, S.F.; Frick, D.N.; Bessman, M.J. Studies on the ADP-ribose pyrophosphatase subfamily of the nudix hydrolases and tentative identification of trgB, a gene associated with tellurite resistance. J. Biol. Chem. 1999, 274, 32318–32324. [Google Scholar] [CrossRef] [Green Version]
  46. Cai, L.; Sutter, B.M.; Li, B.; Tu, B.P. Acetyl-CoA induces cell growth and proliferation by promoting the acetylation of histones at growth genes. Mol. Cell 2011, 42, 426–437. [Google Scholar] [CrossRef] [Green Version]
  47. Polakis, P. Wnt signaling and cancer. Genes Dev. 2000, 14, 1837–1851. [Google Scholar] [CrossRef] [Green Version]
  48. Polakis, P. Wnt signaling in cancer. Cold Spring Harb. Perspect. Biol. 2012, 4. [Google Scholar] [CrossRef] [Green Version]
  49. Dimitriadis, A.; Vincan, E.; Mohammed, I.M.; Roczo, N.; Phillips, W.A.; Baindur-Hudson, S. Expression of Wnt genes in human colon cancers. Cancer Lett. 2001, 166, 185–191. [Google Scholar] [CrossRef]
  50. Holcombe, R.F.; Marsh, J.L.; Waterman, M.L.; Lin, F.; Milovanovic, T.; Truong, T. Expression of Wnt ligands and Frizzled receptors in colonic mucosa and in colon carcinoma. Mol. Pathol. 2002, 55, 220–226. [Google Scholar] [CrossRef]
  51. de Sousa, E.M.; Vermeulen, L.; Richel, D.; Medema, J.P. Targeting Wnt signaling in colon cancer stem cells. Clin. Cancer Res. 2011, 17, 647–653. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  52. Clements, W.M.; Lowy, A.M.; Groden, J. Adenomatous polyposis coli/beta-catenin interaction and downstream targets: altered gene expression in gastrointestinal tumors. Clin. Colorectal. Cancer 2003, 3, 113–120. [Google Scholar] [CrossRef] [PubMed]
  53. Sanchez-Tillo, E.; de Barrios, O.; Siles, L.; Cuatrecasas, M.; Castells, A.; Postigo, A. beta-catenin/TCF4 complex induces the epithelial-to-mesenchymal transition (EMT)-activator ZEB1 to regulate tumor invasiveness. Proc. Natl. Acad. Sci. USA 2011, 108, 19204–19209. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  54. D’Abaco, G.M.; Whitehead, R.H.; Burgess, A.W. Synergy between Apc min and an activated ras mutation is sufficient to induce colon carcinomas. Mol. Cell Biol. 1996, 16, 884–891. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  55. Janssen, K.P.; Alberici, P.; Fsihi, H.; Gaspar, C.; Breukel, C.; Franken, P.; Rosty, C.; Abal, M.; El Marjou, F.; Smits, R.; et al. APC and oncogenic KRAS are synergistic in enhancing Wnt signaling in intestinal tumor formation and progression. Gastroenterology 2006, 131, 1096–1109. [Google Scholar] [CrossRef] [PubMed]
  56. Ahn, S.Y.; Yang, J.H.; Kim, N.H.; Lee, K.; Cha, Y.H.; Yun, J.S.; Kang, H.E.; Lee, Y.; Choi, J.; Kim, H.S.; et al. Anti-helminthic niclosamide inhibits Ras-driven oncogenic transformation via activation of GSK-3. Oncotarget 2017, 8, 31856–31863. [Google Scholar] [CrossRef] [Green Version]
  57. Yao, Y.; Sun, S.; Wang, J.; Fei, F.; Dong, Z.; Ke, A.W.; He, R.; Wang, L.; Zhang, L.; Ji, M.B.; et al. Canonical Wnt Signaling Remodels Lipid Metabolism in Zebrafish Hepatocytes following Ras Oncogenic Insult. Cancer Res. 2018, 78, 5548–5560. [Google Scholar] [CrossRef] [Green Version]
  58. Veech, R.L. The therapeutic implications of ketone bodies: the effects of ketone bodies in pathological conditions: ketosis, ketogenic diet, redox states, insulin resistance, and mitochondrial metabolism. Prostaglandins Leukot. Essent. Fatty Acids 2004, 70, 309–319. [Google Scholar] [CrossRef]
  59. Koo, S.H. Nonalcoholic fatty liver disease: molecular mechanisms for the hepatic steatosis. Clin. Mol. Hepatol. 2013, 19, 210–215. [Google Scholar] [CrossRef]
  60. Cabral, M.; Martin-Venegas, R.; Moreno, J.J. Role of arachidonic acid metabolites on the control of non-differentiated intestinal epithelial cell growth. Int. J. Biochem. Cell Biol. 2013, 45, 1620–1628. [Google Scholar] [CrossRef]
  61. Louie, S.M.; Roberts, L.S.; Mulvihill, M.M.; Luo, K.; Nomura, D.K. Cancer cells incorporate and remodel exogenous palmitate into structural and oncogenic signaling lipids. Biochim. Biophys. Acta 2013, 1831, 1566–1572. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  62. Niso-Santano, M.; Malik, S.A.; Pietrocola, F.; Bravo-San Pedro, J.M.; Marino, G.; Cianfanelli, V.; Ben-Younes, A.; Troncoso, R.; Markaki, M.; Sica, V.; et al. Unsaturated fatty acids induce non-canonical autophagy. EMBO J. 2015, 34, 1025–1041. [Google Scholar] [CrossRef] [PubMed]
  63. Tan, S.H.; Shui, G.; Zhou, J.; Li, J.J.; Bay, B.H.; Wenk, M.R.; Shen, H.M. Induction of autophagy by palmitic acid via protein kinase C-mediated signaling pathway independent of mTOR (mammalian target of rapamycin). J. Biol. Chem. 2012, 287, 14364–14376. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  64. Fatima, S.; Hu, X.; Huang, C.; Zhang, W.; Cai, J.; Huang, M.; Gong, R.H.; Chen, M.; Ho, A.H.M.; Su, T.; et al. High-fat diet feeding and palmitic acid increase CRC growth in beta2AR-dependent manner. Cell Death Dis 2019, 10, 711. [Google Scholar] [CrossRef] [Green Version]
  65. Fujise, T.; Iwakiri, R.; Kakimoto, T.; Shiraishi, R.; Sakata, Y.; Wu, B.; Tsunada, S.; Ootani, A.; Fujimoto, K. Long-term feeding of various fat diets modulates azoxymethane-induced colon carcinogenesis through Wnt/beta-catenin signaling in rats. Am. J. Physiol. Gastrointest. Liver Physiol. 2007, 292, G1150–1156. [Google Scholar] [CrossRef]
  66. Takada, R.; Satomi, Y.; Kurata, T.; Ueno, N.; Norioka, S.; Kondoh, H.; Takao, T.; Takada, S. Monounsaturated fatty acid modification of Wnt protein: its role in Wnt secretion. Dev. Cell 2006, 11, 791–801. [Google Scholar] [CrossRef] [Green Version]
  67. Tian, H.; Liu, C.; Zou, X.; Wu, W.; Zhang, C.; Yuan, D. MiRNA-194 Regulates Palmitic Acid-Induced Toll-Like Receptor 4 Inflammatory Responses in THP-1 Cells. Nutrients 2015, 7, 3483–3496. [Google Scholar] [CrossRef] [Green Version]
  68. Wolfson, B.; Lo, P.K.; Yao, Y.; Li, L.; Wang, H.; Zhou, Q. Impact of miR-140 Deficiency on Non-Alcoholic Fatty Liver Disease. Mol. Nutr. Food Res. 2018, 62, e1800189. [Google Scholar] [CrossRef]
  69. Yue, Q.; Zhao, C.; Wang, Y.; Zhao, L.; Zhu, Q.; Li, G.; Wu, N.; Jia, D.; Ma, C. Downregulation of growth arrestspecific transcript 5 alleviates palmitic acidinduced myocardial inflammatory injury through the miR26a/HMGB1/NFkappaB axis. Mol. Med. Rep. 2018, 18, 5742–5750. [Google Scholar] [CrossRef] [Green Version]
  70. Binker-Cosen, M.J.; Richards, D.; Oliver, B.; Gaisano, H.Y.; Binker, M.G.; Cosen-Binker, L.I. Palmitic acid increases invasiveness of pancreatic cancer cells AsPC-1 through TLR4/ROS/NF-kappaB/MMP-9 signaling pathway. Biochem. Biophys. Res. Commun. 2017, 484, 152–158. [Google Scholar] [CrossRef]
  71. De Robertis, M.; Massi, E.; Poeta, M.L.; Carotti, S.; Morini, S.; Cecchetelli, L.; Signori, E.; Fazio, V.M. The AOM/DSS murine model for the study of colon carcinogenesis: From pathways to diagnosis and therapy studies. J. Carcinog 2011, 10, 9. [Google Scholar] [CrossRef] [PubMed]
  72. Livak, K.J.; Schmittgen, T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25, 402–408. [Google Scholar] [CrossRef] [PubMed]
  73. Mane, D.R.; Kale, A.D.; Belaldavar, C. Validation of immunoexpression of tenascin-C in oral precancerous and cancerous tissues using ImageJ analysis with novel immunohistochemistry profiler plugin: An immunohistochemical quantitative analysis. J. Oral. Maxillofac. Pathol. 2017, 21, 211–217. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  74. Varghese, F.; Bukhari, A.B.; Malhotra, R.; De, A. IHC Profiler: an open source plugin for the quantitative evaluation and automated scoring of immunohistochemistry images of human tissue samples. PLoS One 2014, 9, e96801. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  75. Park, S.; Oh, J.; Kim, Y.I.; Choe, S.K.; Chun, C.H.; Jin, E.J. Suppression of ABCD2 dysregulates lipid metabolism via dysregulation of miR-141:ACSL4 in human osteoarthritis. Cell Biochem. Funct. 2018, 36, 366–376. [Google Scholar] [CrossRef]
Cancers 12 00576 g001 550
Figure 1. Dysfunction of lipid metabolism in KrasG12D colorectal cancer (CRC) cells. (A) BODIPY staining and (B) lipid reactive oxygen species (ROS) staining using KrasG12D and KrasWT cell lines. Positive cells were counted for every 50 cells in 3 different fields at 400× magnification. Results shown are representative of at least 3 independent experiments. Scale bars: 100 μm. (C) Expression level of genes involved in lipid metabolism in KrasG12D CRC cells and presented as the fold change of KrasWT CRC cells. Rn18s was used as an endogenous control. Results are representative of at least 3 independent experiments. (D) Immunohistochemical staining with CPT1, FABP4, and SCD1, and positive cells were counted (n = 4). Scale bars: 100 μm. (E) GSEA analysis using GEO datasets (CRC patient biopsy dataset, GSE41258 and KrasG12D transfected CRC cell line dataset, GSE12398). Values are presented as means + SD. A two-tailed Student’s t-test was used for statistical analysis. * p ≤ 0.05, *** p < 0.001, **** p < 0.0001.
Figure 1. Dysfunction of lipid metabolism in KrasG12D colorectal cancer (CRC) cells. (A) BODIPY staining and (B) lipid reactive oxygen species (ROS) staining using KrasG12D and KrasWT cell lines. Positive cells were counted for every 50 cells in 3 different fields at 400× magnification. Results shown are representative of at least 3 independent experiments. Scale bars: 100 μm. (C) Expression level of genes involved in lipid metabolism in KrasG12D CRC cells and presented as the fold change of KrasWT CRC cells. Rn18s was used as an endogenous control. Results are representative of at least 3 independent experiments. (D) Immunohistochemical staining with CPT1, FABP4, and SCD1, and positive cells were counted (n = 4). Scale bars: 100 μm. (E) GSEA analysis using GEO datasets (CRC patient biopsy dataset, GSE41258 and KrasG12D transfected CRC cell line dataset, GSE12398). Values are presented as means + SD. A two-tailed Student’s t-test was used for statistical analysis. * p ≤ 0.05, *** p < 0.001, **** p < 0.0001.
Cancers 12 00576 g001
Cancers 12 00576 g002 550
Figure 2. Decreased level of peroxisomal Nudt7 is observed in KrasG12D CRC dysregulation. (A) Expression level of Nudt7 in CRC tumors using GSE8671 dataset and presented as the fold change compared with normal. (B) Expression level of Nudt7 in tumors or adjacent non-tumor areas of KrasG12D and KrasWT CRC. Rn18s was used as an endogenous control (n = 3). (C) NUDT7 expression was analyzed via immunohistochemistry using tamoxifen-inducible Villin-CreERT2; Apcf/f; Trp53f/f; tetO-LSL-KrasG12D mice (KrasOFF and KrasON) and human patients (KrasWT and KrasG12D). Positive cells were counted for every 100 cells in 3 different fields at 200× magnification. Results are representative of at least 3 independent experiments. Scale bars: 100 μm. Values are means + SD. An unpaired Student’s t-test was used for statistical analysis. *** p < 0.001, **** p < 0.0001.
Figure 2. Decreased level of peroxisomal Nudt7 is observed in KrasG12D CRC dysregulation. (A) Expression level of Nudt7 in CRC tumors using GSE8671 dataset and presented as the fold change compared with normal. (B) Expression level of Nudt7 in tumors or adjacent non-tumor areas of KrasG12D and KrasWT CRC. Rn18s was used as an endogenous control (n = 3). (C) NUDT7 expression was analyzed via immunohistochemistry using tamoxifen-inducible Villin-CreERT2; Apcf/f; Trp53f/f; tetO-LSL-KrasG12D mice (KrasOFF and KrasON) and human patients (KrasWT and KrasG12D). Positive cells were counted for every 100 cells in 3 different fields at 200× magnification. Results are representative of at least 3 independent experiments. Scale bars: 100 μm. Values are means + SD. An unpaired Student’s t-test was used for statistical analysis. *** p < 0.001, **** p < 0.0001.
Cancers 12 00576 g002
Cancers 12 00576 g003 550
Figure 3. Nudt7 is involved in the progression of KrasG12D CRC. (A,B) Cells transduced with lentivirus containing the control and Nudt7 in LS174T cells were grafted into nude mice. Each tumor mass was measured and the expression level of Nudt7 was confirmed by real-time PCR and is presented as the fold change compared with the control (Con). Results are representative of at least 4 independent experiments. (C) BODIPY staining in control and Nudt7-grafted tumors, and BODIPY-positive cells were counted for every 50 cells in 3 different fields. Results are representative of at least 3 independent experiments. Scale bars: 50 μm. (D) Expression level of lipid metabolic genes and presented as the fold change compared with Con. Rn18s was used as an endogenous control. Results are representative of at least 3 independent experiments. (E) Immunohistochemical staining with cytokeratin 19 (CK19), Ki67, FASN, ACC, CPT1, FABP4, and SCD1. CK19 was used as a marker for epithelial tissue. Positive cells were counted for every 100 cells in 3 different fields at 200× magnification. Results are representative of at least 3 independent experiments. The dotted line boxes were enlarged in the upper right corner of each image. Scale bars: 100 μm. Values are means + SD. An unpaired Student’s t-test was used for statistical analysis. * p ≤ 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.
Figure 3. Nudt7 is involved in the progression of KrasG12D CRC. (A,B) Cells transduced with lentivirus containing the control and Nudt7 in LS174T cells were grafted into nude mice. Each tumor mass was measured and the expression level of Nudt7 was confirmed by real-time PCR and is presented as the fold change compared with the control (Con). Results are representative of at least 4 independent experiments. (C) BODIPY staining in control and Nudt7-grafted tumors, and BODIPY-positive cells were counted for every 50 cells in 3 different fields. Results are representative of at least 3 independent experiments. Scale bars: 50 μm. (D) Expression level of lipid metabolic genes and presented as the fold change compared with Con. Rn18s was used as an endogenous control. Results are representative of at least 3 independent experiments. (E) Immunohistochemical staining with cytokeratin 19 (CK19), Ki67, FASN, ACC, CPT1, FABP4, and SCD1. CK19 was used as a marker for epithelial tissue. Positive cells were counted for every 100 cells in 3 different fields at 200× magnification. Results are representative of at least 3 independent experiments. The dotted line boxes were enlarged in the upper right corner of each image. Scale bars: 100 μm. Values are means + SD. An unpaired Student’s t-test was used for statistical analysis. * p ≤ 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.
Cancers 12 00576 g003
Cancers 12 00576 g004 550
Figure 4. AOM/DSS (azoxymethane/dextran sulfate sodium)-treated Nudt7−/− mice increases the possibility of CRC development. (A) Mice were treated with AOM/DSS and polyp number was counted. Scale bars: 2 cm. (B,C) Immunohistochemistry with hematoxylin and eosin (H&E), Ki67, F4/80, LY6G, NUDT7, ACOX1, and SCD1 (n = 4) and positive cells were counted for every 100 cells in 3 different fields at 100× magnification in Nudt7+/+ and Nudt7−/− colons treated with AOM/DSS. Results are representative of at least 3 independent experiments. Scale bars: 200 μm. (D,E) Transcriptional levels of proliferation and inflammatory marker genes and KrasG12D target genes in Nudt7+/+ and Nudt7−/− colons treated with AOM/DSS. Rn18s was used as an endogenous control. Results are representative of at least 3 independent experiments. Values are means + SD. An unpaired Student’s t-test was used for statistical analysis. * p ≤ 0.01, ** p < 0.01, *** p < 0.01, **** p < 0.0001.
Figure 4. AOM/DSS (azoxymethane/dextran sulfate sodium)-treated Nudt7−/− mice increases the possibility of CRC development. (A) Mice were treated with AOM/DSS and polyp number was counted. Scale bars: 2 cm. (B,C) Immunohistochemistry with hematoxylin and eosin (H&E), Ki67, F4/80, LY6G, NUDT7, ACOX1, and SCD1 (n = 4) and positive cells were counted for every 100 cells in 3 different fields at 100× magnification in Nudt7+/+ and Nudt7−/− colons treated with AOM/DSS. Results are representative of at least 3 independent experiments. Scale bars: 200 μm. (D,E) Transcriptional levels of proliferation and inflammatory marker genes and KrasG12D target genes in Nudt7+/+ and Nudt7−/− colons treated with AOM/DSS. Rn18s was used as an endogenous control. Results are representative of at least 3 independent experiments. Values are means + SD. An unpaired Student’s t-test was used for statistical analysis. * p ≤ 0.01, ** p < 0.01, *** p < 0.01, **** p < 0.0001.
Cancers 12 00576 g004
Cancers 12 00576 g005 550
Figure 5. Suppression of Nudt7 increases β-catenin signaling. (A) Canonical pathway was analyzed using IPA software (Qiagen, Redwood, CA, USA) from microarray data of Nudt7+/+ and Nudt7−/− colons treated with AOM/DSS. (B) Active z-score of disease and biological functions or molecular and cellular functions were analyzed using IPA software. (C) GSEA analysis using GEO datasets (CRC patient biopsy dataset, GSE41258 and KrasG12D mutation CRC cell line dataset, GSE97023) and expression levels of Nudt7 and Ctnnb1. (D) Immunohistochemical staining with β-catenin and CK19 and positive cell count in Nudt7+/+ and Nudt7−/− mice treated with AOM/DSS (n = 4; 100× magnification; scale bars: 200 μm) and KrasG12D-derived CRC patient (n = 4; β-catenin, 100× magnification, scale bars: 200 μm; CK19, 200× magnification, scale bars: 100 μm) and positive cells were counted for every 100 cells in 3 different fields. CK19 was used as a marker for epithelial tissue. Results are representative of at least 3 independent experiments. The dotted line boxes were enlarged in the bottom left corner of each image. (E) Transcriptional levels of β-catenin target genes and presented as the fold change compared with Nudt7−/− mice. Rn18s was used as an endogenous control. Results are representative of at least 3 independent experiments. Values are means + SD. An unpaired Student’s t-test was used for statistical analysis. * p ≤ 0.05, ** p < 0.01, *** p < 0.01, **** p < 0.0001.
Figure 5. Suppression of Nudt7 increases β-catenin signaling. (A) Canonical pathway was analyzed using IPA software (Qiagen, Redwood, CA, USA) from microarray data of Nudt7+/+ and Nudt7−/− colons treated with AOM/DSS. (B) Active z-score of disease and biological functions or molecular and cellular functions were analyzed using IPA software. (C) GSEA analysis using GEO datasets (CRC patient biopsy dataset, GSE41258 and KrasG12D mutation CRC cell line dataset, GSE97023) and expression levels of Nudt7 and Ctnnb1. (D) Immunohistochemical staining with β-catenin and CK19 and positive cell count in Nudt7+/+ and Nudt7−/− mice treated with AOM/DSS (n = 4; 100× magnification; scale bars: 200 μm) and KrasG12D-derived CRC patient (n = 4; β-catenin, 100× magnification, scale bars: 200 μm; CK19, 200× magnification, scale bars: 100 μm) and positive cells were counted for every 100 cells in 3 different fields. CK19 was used as a marker for epithelial tissue. Results are representative of at least 3 independent experiments. The dotted line boxes were enlarged in the bottom left corner of each image. (E) Transcriptional levels of β-catenin target genes and presented as the fold change compared with Nudt7−/− mice. Rn18s was used as an endogenous control. Results are representative of at least 3 independent experiments. Values are means + SD. An unpaired Student’s t-test was used for statistical analysis. * p ≤ 0.05, ** p < 0.01, *** p < 0.01, **** p < 0.0001.
Cancers 12 00576 g005
Cancers 12 00576 g006 550
Figure 6. Accumulated palmitic acid is responsible for activation of β-catenin signaling. (A) Lipidomics was applied and the expression level of palmitic acid (PA) was analyzed in CRC tumors or shNudt7 introduced KrasWT CRC cells (left panel) (n = 4). The efficiency of shNudt7 was confirmed using KrasWT CRC cells (right panel). (B) KrasWT Caco2 cells were introduced with Nudt7 or shNudt7 in the presence of PA and the expression level of β-catenin was analyzed by real-time PCR and represented as the fold change compared with the negative control (-palmitic acid/-shNudt7/-Nudt7). Results are representative of at least 3 independent experiments. Rn18s was used as an endogenous control. (C) Schematic diagram of generating Chi or Chi/PA film. (D) Chi or Chi/PA film was attached in the colon of Nudt7+/+ mice for one week and polyp number was counted. Scale bars: 0.5 cm. (E) Immunohistochemistry with H&E, NUDT7, Ki67, CD45, β-catenin, PCNA, and F4/80 (n = 5) colon-attached Chi or Chi/PA film. Results are representative of at least 3 independent experiments and for every 100 cells in 3 different fields at 100× magnification. Scale bars: 200 μm. (F) Expression level of CRC-related genes in colon-attached Chi or Chi/PA film and represented as the fold change compared with colon-attached Chi film. Results are representative of at least 3 independent experiments. * p ≤ 0.05, ** p < 0.01, *** p < 0.01, **** p < 0.0001.
Figure 6. Accumulated palmitic acid is responsible for activation of β-catenin signaling. (A) Lipidomics was applied and the expression level of palmitic acid (PA) was analyzed in CRC tumors or shNudt7 introduced KrasWT CRC cells (left panel) (n = 4). The efficiency of shNudt7 was confirmed using KrasWT CRC cells (right panel). (B) KrasWT Caco2 cells were introduced with Nudt7 or shNudt7 in the presence of PA and the expression level of β-catenin was analyzed by real-time PCR and represented as the fold change compared with the negative control (-palmitic acid/-shNudt7/-Nudt7). Results are representative of at least 3 independent experiments. Rn18s was used as an endogenous control. (C) Schematic diagram of generating Chi or Chi/PA film. (D) Chi or Chi/PA film was attached in the colon of Nudt7+/+ mice for one week and polyp number was counted. Scale bars: 0.5 cm. (E) Immunohistochemistry with H&E, NUDT7, Ki67, CD45, β-catenin, PCNA, and F4/80 (n = 5) colon-attached Chi or Chi/PA film. Results are representative of at least 3 independent experiments and for every 100 cells in 3 different fields at 100× magnification. Scale bars: 200 μm. (F) Expression level of CRC-related genes in colon-attached Chi or Chi/PA film and represented as the fold change compared with colon-attached Chi film. Results are representative of at least 3 independent experiments. * p ≤ 0.05, ** p < 0.01, *** p < 0.01, **** p < 0.0001.
Cancers 12 00576 g006

Share and Cite

MDPI and ACS Style

Song, J.; Park, S.; Oh, J.; Kim, D.; Ryu, J.H.; Park, W.C.; Baek, I.-J.; Cheng, X.; Lu, X.; Jin, E.-J. NUDT7 Loss Promotes KrasG12D CRC Development. Cancers 2020, 12, 576. https://doi.org/10.3390/cancers12030576

AMA Style

Song J, Park S, Oh J, Kim D, Ryu JH, Park WC, Baek I-J, Cheng X, Lu X, Jin E-J. NUDT7 Loss Promotes KrasG12D CRC Development. Cancers. 2020; 12(3):576. https://doi.org/10.3390/cancers12030576

Chicago/Turabian Style

Song, Jinsoo, Sujeong Park, Jinjoo Oh, Deokha Kim, Ji Hyun Ryu, Won Cheol Park, In-Jeoung Baek, Xi Cheng, Xin Lu, and Eun-Jung Jin. 2020. "NUDT7 Loss Promotes KrasG12D CRC Development" Cancers 12, no. 3: 576. https://doi.org/10.3390/cancers12030576

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop